Telemetry Investments, L.L.C. Fate Therapeutics Inc Transaction History

Telemetry Investments, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$8.75 - $16.29 $350,000 - $651,600	-40,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$9.16 - $13.48 $276,632 - $407,096	-30,200 Reduced 43.02%	40,000 $454,000
Q1 2018 May 15, 2018	SELL	$6.3 - $13.77 $131,814 - $288,109	-20,923 Reduced 22.96%	70,200 $685,000
Q4 2017 Feb 14, 2018	SELL	$3.94 - $6.64 $271,375 - $457,343	-68,877 Reduced 43.05%	91,123 $557,000
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $416,000 - $689,599	160,000	160,000 $634,000

190

123M

15K

14K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $340M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Telemetry Investments, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Telemetry Investments, L.L.C. with notifications on news.